

PRESS RELEASE

Date 1 July 2021
Contact Investor Relations: Felix Burkhard, CFO Galenica Group
Media Relations: Christina Hertig, Head of Corporate Communications
Subject Verfora acquires Spagyros Ltd. and expands its product portfolio

Verfora acquires Spagyros Ltd. and expands its range of phytotherapy and complementary medicines

Verfora, a subsidiary of Galenica, and Spagyros, a successful Swiss company in the manufacture and marketing of complementary medicines, have been maintaining a strategic partnership since 2018 that was also supported by Galenica with a small minority stake in Spagyros.

With effect as of September 2021, Verfora will now acquire 100% of the share capital of Spagyros Ltd. This expansion step will not only enable Verfora in the future to meet the growing demand for phytotherapy and complementary medicines through its own products, but the company will also be able to strengthen pharmacies and drugstores with the addition of a range of products requiring intensive consultation. At the same time, this acquisition further strengthens Verfora's leading position in the Swiss consumer healthcare (CHC) market.

Phytotherapy and complementary medicines: a consultation-intensive field with growth potential

With the acquisition of Spagyros, Verfora is strengthening and opening up the interesting fields of phytotherapy, gemmotherapy, spagyrics and homoeopathy. These include well-known brands such as Spagyrom® (sore throat lozenges and cold drops), Spagymun® Abwehrkräfte (defences) or Spagyros Ribes nigrum® Gemmospray (mouth spray for colds and hay fever). Furthermore, Spagyros offers comprehensive education and training programmes in the fields of spagyrics, homoeopathy and gemmotherapy, which are recognised by the FPH (Swiss Association of Pharmacists), and the Swiss Druggists' Association.

Since its foundation in 1985, Spagyros has been pursuing the goal of producing top-quality phytotherapy and complementary medicines. Spagyros is a GMP (Good Manufacturing Practice) - certified pharmaceutical company that manufactures most of its medicines in Switzerland with a lot of handcraft. Spagyros employs around 35 people at two production sites in Worb (Canton of Berne) and Malmaison, St-Brais (Canton of Jura).

Spagyros and Galenica have been maintaining a strategic partnership since 2018, supported by Galenica with a small minority stake in Spagyros Ltd. As of September 2021, Verfora will now acquire 100% of the share capital of Spagyros Ltd.

Spagyros will be managed as an independent Business Unit of the Products & Marketing Service Unit within the Galenica Group. All employees and their network of prescribers, pharmacists and druggists will be taken on. The production sites in Worb and Malmaison, St-Brais, including their own cultivation of medicinal plants, will also continue to operate. Spagyros currently generates total market sales of approximately CHF 10 million at public prices through pharmacies, drugstores, doctors and therapists.

Date 1 July 2021
Page 2/2
Subject Verfora acquires Spagyros Ltd. and expands its product portfolio

Jacqueline Ryffel, who successfully managed and developed Spagyros over the past 24 years in her capacity as Managing Director and Chairwomen of the Board of Directors, will step down from her position at the end of August 2021. Under her leadership, the original company of seven employees has developed into a team of around 35 very dedicated specialists. In addition to his role as CEO of Verfora, Stefan Wälti will also take over the management of Spagyros from September 2021 onwards. However, Jacqueline Ryffel will be available to Verfora in an advisory capacity to share her extensive expertise until early 2023.

Both parties have agreed not to disclose the purchase price.

Dates for the diary

3 August 2021:	Publication of the half-year report 2021 of the Galenica Group
20 January 2022:	Publication of 2021 sales figures of the Galenica Group
8 March 2022:	Publication of the results of the 2021 financial year of the Galenica Group
11 May 2022:	Annual General Meeting of Galenica Ltd.

For further information, please contact:

Media Relations:

Christina Hertig, Head of Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Felix Burkhard, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

***Galenica** is Switzerland's leading, completely integrated healthcare service provider. With over 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica further develops and offers well-known own brands and products, exclusive brands and products from business partners as well as a variety of on-site health services and tests for customers. Galenica is also the leading provider of pre-wholesale and wholesale distribution services as well as database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446).*

Additional information concerning Galenica can be found at www.galenica.com.

***Spagyros Ltd.** is an innovative company that is highly successful in the manufacture and marketing of complementary medicines. Since it was first founded in 1985, it has been shaped by people who constantly strive to produce top-quality medicines. Spagyros is a GMP-certified pharmaceutical company that manufactures all medicines in Switzerland. Spagyros AG produces homoeopathic, spagyric, gemmotherapeutic and phytotherapeutic medicines. It adheres to the highest ethical standards and is guided by tradition. Even today, all medicines are exclusively handcrafted in accordance with the rules set forth by Hahnemann, Baumann, the HAB (Book of Homoeopathic Medicines) and the Ph. Eur. (European Pharmacopoeia).*

You can find additional information about Spagyros Ltd. at www.spagyros.ch.